Improve Research Reproducibility A Bio-protocol resource

Microbiology


Categories

Protocols in Current Issue
Protocols in Past Issues
0 Q&A 9421 Views Aug 5, 2014
Hepatitis E virus (HEV) is one of the main causes of acute hepatitis worldwide. Infections are particularly severe in pregnant women and chronic hepatitis E is known to occur in immunocompromised patients. Current therapy (ribavirin or pegylated alpha interferon) has severe side effects and cannot be employed in all patients. In order to evaluate potential new inhibitors of HEV replication, a luminescence-based replicon assay is particularly useful since it offers a rapid read-out and does not pose any biosafety risks (Debing et al., 2014).



We use cookies to improve your user experience on this site. By using our website, you agree to the storage of cookies on your computer.